PTEN
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Also known as: BZS, MHAM, MMAC1, PTEN_HUMAN, PTEN1, TEP1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P60484
- Gene
- PTEN
- Ensembl
- ENSG00000171862
- Chromosome
- 10
- Canonical length
- 403 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol,Mid piece,Principal piece
- Secretome location
- Intracellular and membrane
OverviewNCBI Gene
This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate energy metabolism in the mitochondria. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2015]
Canonical amino-acid sequenceUniProt
403 residues, UniProt reviewed canonical sequence.
>P60484|PTEN
1 MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK
61 HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA
121 AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY
181 LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY
241 FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI
301 DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS
361 SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PTEN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 51 nTPM
Expression across tissuesHPA
Tissue
- cervix: 51 nTPM
- placenta: 47 nTPM
- thymus: 41 nTPM
- adipose tissue: 41 nTPM
- liver: 40 nTPM
- smooth muscle: 34 nTPM
Single-cell type
- choroid plexus epithelial cells: 282 nCPM
- microglia: 280 nCPM
- brain excitatory neurons: 240 nCPM
- distal convoluted tubule cells: 220 nCPM
- renal collecting duct principal cells: 211 nCPM
- papillary tip epithelial cells: 211 nCPM
Immune cell
- neutrophil: 63 nTPM
- eosinophil: 28 nTPM
- intermediate monocyte: 23 nTPM
- basophil: 23 nTPM
- non-classical monocyte: 17 nTPM
- classical monocyte: 15 nTPM
Brain region
- cerebral cortex: 34 nTPM
- cerebellum: 32 nTPM
- basal ganglia: 21 nTPM
- hippocampal formation: 21 nTPM
- hypothalamus: 20 nTPM
- thalamus: 19 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PTEN.
Disease | AllUniProt
Conditions PTEN is implicated in, by any mechanism.
- Cowden syndrome 1 (CWS1) MIM:158350
- Lhermitte-Duclos disease (LDD) MIM:158350
- Squamous cell carcinoma of the head and neck (HNSCC) MIM:275355
- Endometrial cancer (ENDMC) MIM:608089
- Glioma 2 (GLM2) MIM:613028
- Prostate cancer (PC) MIM:176807
- Macrocephaly/autism syndrome (MCEPHAS) MIM:605309
Disease | GeneticClinVar
1,298 pathogenic / likely-pathogenic of 4,043 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- PTEN hamartoma tumor syndrome
- Cowden syndrome 1
- Hereditary cancer-predisposing syndrome
- Macrocephaly-autism syndrome
- Neoplasm
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.51
- gnomAD pLI
- 0.26
- gnomAD missense Z
- 3.49
- DepMap mean gene effect
- 0.42
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adult behavior
- apoptotic process
- cell migration
- cell motility
- cellular response to electrical stimulus
- central nervous system development
- central nervous system myelin maintenance
- central nervous system neuron axonogenesis
- dendritic spine morphogenesis
- dentate gyrus development
- forebrain morphogenesis
- heart development
- learning or memory
- locomotor rhythm
- locomotory behavior
- maternal behavior
- multicellular organismal response to stress
- negative regulation of axonogenesis
- negative regulation of cell cycle G1/S phase transition
- negative regulation of cell migration
- negative regulation of cell population proliferation
- negative regulation of cell size
- negative regulation of cellular senescence
- negative regulation of epithelial to mesenchymal transition
- negative regulation of excitatory postsynaptic potential
- negative regulation of focal adhesion assembly
- negative regulation of G1/S transition of mitotic cell cycle
- negative regulation of keratinocyte migration
- negative regulation of neuron projection development
- negative regulation of organ growth
- negative regulation of osteoblast differentiation
- negative regulation of peptidyl-serine phosphorylation
- negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- negative regulation of vascular associated smooth muscle cell proliferation
- negative regulation of wound healing, spreading of epidermal cells
- neuron-neuron synaptic transmission
- phosphatidylinositol 3-kinase/protein kinase B signal transduction
- phosphatidylinositol biosynthetic process
- phosphatidylinositol dephosphorylation
- positive regulation of cell population proliferation
- positive regulation of excitatory postsynaptic potential
- positive regulation of intracellular signal transduction
- positive regulation of transcription by RNA polymerase II
- positive regulation of ubiquitin-dependent protein catabolic process
- postsynaptic density assembly
- prepulse inhibition
- presynaptic membrane assembly
- protein dephosphorylation
- protein stabilization
- regulation of neuron projection development
- regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- regulation of protein stability
- rhythmic synaptic transmission
- social behavior
- spindle assembly involved in female meiosis
- synapse assembly
- synapse maturation
- negative regulation of synaptic vesicle clustering
Molecular functions
- anaphase-promoting complex binding
- beta-catenin binding
- enzyme binding
- identical protein binding
- inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity
- inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity
- lipid binding
- molecular function inhibitor activity
- PDZ domain binding
- phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity
- phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity
- phosphatidylinositol-3-phosphate phosphatase activity
- phosphoprotein phosphatase activity
- protein serine/threonine phosphatase activity
- protein tyrosine phosphatase activity
- ubiquitin ligase activator activity
- ubiquitin-specific protease binding
- phosphatidylinositol phosphate phosphatase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Tyrosine-specific protein phosphatases domain
- Protein-tyrosine phosphatase, catalytic
- Tensin phosphatase, C2 domain
- Protein-tyrosine phosphatase, active site
- Protein-tyrosine phosphatase-like
- Tensin-type phosphatase domain
- C2 domain superfamily
- Dual-specificity lipid and protein phosphatase
- C2 domain of PTEN tumour-suppressor protein
- Polymorphic toxin system, DSP-PTPase phosphatase
- Bifunctional phosphatidylinositol trisphosphate phosphatase/dual specificity phosphatase PTEN
- PTEN, phosphatase domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PTEN in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PTEN as an antibody target. Whether an autoantibody or antibody against PTEN could matter depends on whether native PTEN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PTEN is annotated as secreted, so native PTEN circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PTEN as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...